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CHA2DS2-VASc and HAS-BLED clinical risk score. Results: Totally, 10,099 patients 
fulfilled our study criterions. The total annualized direct cost of NVAF patient was 
1,627.9 euro ±1,076.6. The main cost component was the hospitalization (68.0%), 
followed by drug use (24.6%) and outpatient services (7.4%). The predictors of the 
total cost were male (RR: 1.37, CI: 1.29-1.45 versus female), incident (RR: 4.60, CI: 4.30-
4.92 versus prevalent patient), switcher (RR: 1.88, CI: 1.72-2.06 versus no switcher), 
CHA2DS2-VASc score (RR: 6.34, CI:5.08-7.92 for score 7 versus score 0) and HAS-BLED 
(RR: 1.36, CI:1.25-1.48 for score > 3 versus score ≤ 3). ConClusions: NVAF places an 
enormous burden on health care system. Hospitalization as major cost driver high-
lights the potential cost-effectiveness of disease management targeted at reducing 
risks of serious cerebrovascular events among NVAF patients.
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objeCtives: The innovative technologies for aortic stenosis (AS) treatment 
require in-depth analysis of the costs associated with disease and comorbidi-
ties. To quantify health care resources consumed by AS patients’ treatment 
(drugs, diagnostic tests, hospital outpatient and inpatient) and estimate the 
total direct costs. Methods: We conducted a retrospective observational 
cohort analysis using data from administrative databases of Local Health 
Authority of Milan in Italy. The study population included all subjects hospi-
talized with principal or secondary AS diagnosis between January 1, 2007 and 
December 31, 2011 (enrollment period). All subjects were observed for two 
years after the first hospitalization (index hospitalization). Patient characteri-
zation was related to the two years before index hospitalization (characteri-
zation period). Data related to hospitalizations, drugs and hospital outpatient 
during both periods were collected for each patient to quantify the resources 
consumption. The hospitalization costs were estimated using DRG tariffs and 
hospital outpatient costs with regional tariffs. The drugs consumption was evalu-
ated through the tear-off tab prices. Results: 919 patients were included (mean 
age 71.3 ± 11.6; 51% males). The mean cost of illness per patient is € 16,271 and € 
13,916, in the characterization and observation period respectively. Of all treated 
patients, 323 (35 %) underwent surgical procedure. The mean cost of illness for 
these patients is € 28,365 and € 8,002, in the characterization and observation 
period respectively. Considering only costs related to cardiovascular disease, the 
mean cost per patient is € 3,470 and € 2,272 in the characterization and obser-
vation period respectively. ConClusions: The cost of illness in AS patients is 
lower in the period after admission, especially when patients underwent cardiac 
valve treatment.
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objeCtives: Hyperkalemia is a metabolic abnormality seen frequently in the 
Emergency Department. The most common condition leading to hyperkalemia is 
missed dialysis in a patient with end stage renal disease (ESRD), but many other 
conditions can predispose an individual to hyperkalemia, such as acute renal fail-
ure, extensive burns, trauma, or severe rhabdomyolysis or severe acidosis. The 
objective of this study was to assess the resource burden on United States emer-
gency room departments due to hyperkalemia. Methods: The number of emer-
gency room (ED/ ER) visits due to hyperkalemia, with International Classification 
of Diseases (ICD-9) code 276.7, were estimated using the Centers for Medicare & 
Medicaid Services (CMS) Agency for Healthcare Research and Quality (AHRQ) 2011 
data for ED visits. A review of recent publications on hyperkalemia management 
was also conducted using the databases Pubmed, Embase, Biosis, Google Scholar 
and Cochrane. Results: The annual number of ED visits with Hyperkalemia as 
one of the diagnoses is estimated to be 814,181 (SE 23,526). The annual number of 
ED visits with Hyperkalemia as the first listed diagnosis is estimated to be 66,989 
(SE 2284. Among the age groups 18-44, 45-64, 65-84, 85+ the majority of ED visits 
were in the 45-64 (36.04%) and 65-84 (39.44%) groups (hyperkalemia as the first 
listed diagnosis). Among the five payer types, Medicare, Medicaid, Private insurance, 
Uninsured and Other, the majority of patients belonged to Medicare (68.41%). The 
trend was similar for patients with Hyperkalemia as one of the diagnosis or first 
diagnosis. ConClusions: This analysis confirms previous findings that hyper-
kalemia is common in the emergency department. There is a need for quick, safe 
and effective treatments for hyperkalemia, which can be easily administered in 
emergency department setting.
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objeCtives: The high prevalence of obesity and overweight leads to frequent use 
of health care resources. Studies aimed at assessment of damages caused by this 
medico-social problem are seen as very important at last years. The main aim of this 
study was to assess burden of obesity and overweight in Russia taking as an example 
three main social diseases: stroke, heart attack, and diabetes mellitus. Methods: 
Available evidence on assessment of costs of management and treatment of obese 
and overweight patients and its relation to the disorders selected were analyzed. 
To measure costs of obesity and overweight for the state budget were used “cost 
of illness” analysis with consideration of risks of stroke, heart attack, and diabetes 
mellitus in the population (G. Oster et al, 2000). Taking into account specific fea-
tures of cost assessment and based on publically available data were developed 
costs were € 56,77 and € 39,18 correspondingly. “The cost-efficiency” analysis 
demonstrated that CER in main group was € 67,58 and CER in control group was € 
72,56. ConClusions: The “cost-efficiency” analysis demonstrated that adminis-
tration of tiazotic acid morpholinium salt in combination with standard therapy 
is more effective and less expensive in ACS patients. The obtained results allow to 
optimize treatment expenditures for a state, insurance companies and patients.
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objeCtives: About two-thirds of stroke survivors develop post-stroke sequelae, 
including spasticity. The burden of post-stroke spasticity (PSS) is high in terms of 
treatment costs and the effects of comorbidities. Our objective was to describe the 
burden of PSS in terms of healthcare resource utilization and costs, and quantify 
the difference between patients who develop PSS and those who do not. Methods: 
This retrospective study used the THIN database. Adult patients with a stroke 
between 1Jan2007 and 31Dec2012 were included. PSS diagnoses were found to be 
under-represented; machine learning methodology was applied to identify poten-
tially undiagnosed PSS. Cases were defined as patients with diagnosed or predicted 
PSS in the 12 months after stroke; for patients without PSS, each stroke acted as 
a control event. PSS cases were matched to controls on age, gender, prior strokes, 
socioeconomic status, and comorbidities, using the nearest neighbour algorithm. 
Direct healthcare resources, including primary care visits, all-cause hospitalisations, 
and specialist referrals during the year post-stroke, were costed out at 2014 GBP 
rates, using public sources. Results: Of the 3,082 PSS cases and 28,753 controls, 
56% were female and 49% were 75 years or older. During the first year, 33% of the 
PSS cases were hospitalised, compared to 9% of the controls. Specialist referrals 
were recorded for 76% of PSS patients and 64% of controls. Primary care utilisation 
was similar for both groups. Total average costs per patient were £1,270 (SD: 772) 
for cases and £631 (SD: 496) for controls. After adjusting for other covariates, a sig-
nificant increase in cost for the PSS patients was found; on average £635 in the 12 
months post-stroke. ConClusions: The costs for patients who develop PSS after 
stroke are twice as high as those for patients who do not develop spasticity, with 
the major driver being the number of hospitalisations.
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objeCtives: Estimate the incremental annual cost after a myocardial infarction 
(MI) Methods: A French representative cohort of patients who had a MI in France 
between 2007 and 2011 was extracted from a claim database of 600,000 patients. 
Costs were calculated from a community perspective, restricted to direct costs and 
from a health insurance scheme perspective. This analysis was performed on sub-
jects still alive one year after MI Results: A total of 1,920 subjects were identified 
with an index MI: 2/3 were males, mean age= 67.2 y, 20.6% had diabetes, 37.6% 
hypercholesterolemia and 82.4% hypertension. Among the 1,920 subjects, 346 died in 
the first year and 3 were lost to follow-up: the cost was performed on 1,571 patients. 
The annual cost from a health insurance scheme perspective approximately tripled 
as it increased from € 3,940 to € 11,914 after a MI: Hospital cost increased from € 1,616 
before the index MI to € 6,470 after hospitalization (the cost of the index hospitaliza-
tion is excluded from the cost); Average community-based care costs increased from 
€ 2,323 before the index MI to € 5,443 after: Travel costs increased from 127€ to 573€ ; 
Fees related to physician consultations increased from 589€ to 1,676€ (annual mean 
number consultations with a general practitioner and a specialist increased from 
7.6 to 10.9 and from 5.4 to 10 respectively); Fees related to laboratory tests increased 
from 139€ to 408€ ; Cost of medicinal products increased from 1,105€ to 2,283€ ; Cost 
of medical non physician health professionals increased from 380€ to 534€ . It should 
be noted that the mean cost related to the index MI hospitalization was € 5,876 . The 
evolution of the costs from a community perspective was similar. ConClusions: 
The economic impact of recurrent cardiovascular events is substantial since health-
care consumption costs almost tripled after the index MI event
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objeCtives: To determine the direct healthcare costs associated with non-valvular 
atrial fibrillation (NVAF). Methods: A population-based cohort study was con-
ducted using administrative data from a local health authority in the Campania 
Region (~1,000,000 inhabitants). NVAF was defined as one or more claims for atrial 
fibrillation (ICD-9-CM code 427.31) between January 1, 2005 and June 30, 2014, where 
none of the claims was associated with cardioversion or cardiac ablation and there 
was no evidence of valve-related diagnoses or procedures. All patients were fol-
lowed from June 30, 2014 until death or end of study follow-up (December 31, 2014). 
The direct costs were reported as average annualized cost (per patient per month 
multiplied by 12). Costs were divided into hospitalizations, outpatient services and 
pharmacy claims. Generalised linear mixed models under gamma distribution were 
used to identify predictors of cumulative healthcare costs. Rate Ratios (RRs) and 95% 
confidence intervals (CIs) were adjusted for age, gender, incident patients, switcher, 
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economic burden of stroke was estimated from a societal perspective with an 
incidence approach.Data were collected from clinical registries and 100 patients 
were included. In the cost calculations, both direct and indirect costs were esti-
mated. Results: Men (78%) consumed more acute care in hospitals, than the 
women (22%). Younger patients (59%) brought a significantly higher burden on 
society compared with the older patients due to the loss of productivity and the 
increased use of resources in health care.41% of patients who have hypertension 
and 45% of patients with alcohol and smoking habits have more prone to stroke 
rather than the patients with other habits and comorbidities.56% of patients have 
the hospital stay of 5-10 days and 52% are using 4-7 medicines per day. From 
the study results ,average direct medical costs and direct nonmedical costs and 
Indirect costs were found to be 2819 ,705 and 754 rupees. In essence, majority of 
the costs for stroke care fall on the hospital,than the long-time care and informal 
care costs and productivity loss. ConClusions: The result of this study can be 
used for further development of the methods for economic analyses as well as for 
analysis of improvements and investments in health care. This aspect highlights 
the enormous importance, for our healthcare service, to invest more in preven-
tion. This cost analysis highlights the importance of clinical pharmacist to set up 
significant prevention programs on selected,high-risk population to reduce the 
economic burden of stroke, which is mostly attributable to hospital and inpatient 
rehabilitation costs immediately after the acute episode.
PCV80
systemAtIC lItertAure reVIew of dIreCt HeAltH CAre Costs for 
CArdIoVAsCulAr eVents Among euroPeAn PAtIents wItH dyslIPIdemIA 
or HIgH CArdIoVAsCulAr rIsk
Nicholson G1, Paoli CJ2, Gandra SR2
1ICON, plc., El Segundo, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA
objeCtives: To review the direct patient-level costs of selected cardiovascular 
events (CVEs): unstable angina, myocardial infarction (MI), cardiac revasculariza-
tion, heart failure, ischemic stroke, acute coronary syndrome in Europe. Methods: 
A systematic literature review was conducted for the period between January 
2000 and March 2015. MEDLINE, EMBASE, ECONLIT, and NHS Economic Evaluation 
Database, conference abstracts from the American Heart Association, American 
College of Cardiology, European Society of Cardiology, European Atherosclerosis 
Society, International Society of the Pharmacoeconomics and Outcomes Research 
and relevant reference lists were searched to identify published articles reporting 
direct costs of one or more CVEs (angina, myocardial infarction, cardiac revas-
cularization, heart failure, ischemic stroke, acute coronary syndrome) in Europe 
(United Kingdom, Germany, Spain, France, Italy, Denmark, Finland, Iceland, 
Norway, Sweden, Belgium, Switzerland, The Netherlands). Two reviewers indepen-
dently assessed studies against inclusion criteria and abstracted cost estimates; 
discrepancies were resolved through discussion or by third reviewer. Studies were 
included if they reported patient-level direct medical costs of one or more CVE(s) 
from a primary economic analysis or cost-effectiveness model among adults with 
identified dyslipidemia or elevated Low Density Lipoprotein-Cholesterol. Costs as 
reported in each study were inflated to 2015 values. Results: Forty-eight studies 
were included for abstraction. Cost estimates for at least one event were found 
in twelve of the thirteen specified countries listed in the search strategy. Annual 
costs of care were highest for stroke (€ 958-€ 10,334), revascularization procedures 
(€ 211-€ 12,383) and MI (€ 558-€ 17,262). The highest cost acute events were revas-
cularization procedures, specifically CABG (€ 10,814- € 25,587), and ischemic stroke 
(€ 3,686-€ 7,978); angina (€ 935-€ 5,214) and heart failure (€ 1,106-€ 4,905) acute costs 
were relatively lower than other conditions. ConClusions: The findings of this 
study highlight the wide variation in the sources and populations used to populate 
economic models in the literature and the substantial costs of CVEs despite event 
type or country of origin.
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objeCtives: The aim is to assess for 2012 the direct and non-directly cost of dia-
betes from a public payer perspective using a new (bottom-up) method and the 
French health insurance medico-administrative database (SNIIRAM). Methods: 
Using information about 60 millions of individuals from the general scheme insur-
ance database (86% of the 69 million individuals insured by all French insurance 
schemes,), we identified people who received care for diabetes if they had an 
ICD-10 diagnosis for diabetes as a long-term chronic disease or at least 3 annual 
reimbursements for anti-diabetic drugs. Costs of all reimbursed expenditures (out-
patient/inpatient care, disability/sickness benefits) were extracted per individual. 
To estimate the burden of diabetes, we identified expenditure items which were 
directly attributable to diabetes (anti-diabetic drugs, medical devices, hospitaliza-
tion with an ICD diabetes code). For other expenditures, we used an incremental 
approach and also econometric model by estimating the additional cost due to 
diabetes (by age and gender) between the diabetic and the non-diabetic popula-
tion. Results: Among 69 million individuals insured by all insurance schemes, 3.3 
million (5%) had diabetes. The overall diabetic population expenditure accounted for 
22 billion, 15% (of the total expenditures reimbursed by the national health insur-
ance). Overall, 11.4 billion (52%) euros were considered as related to diabetes care. 
Reimbursements directly attributable to diabetes accounted for 2.6 billion (23% of 
the 11.4 billion euros) and other costs, mostly related to complications, for 8.8 billion 
(77%). Inpatient care represented the main part of the overall cost of diabetes care 
(22%) together with drugs (20%) and medical auxiliaries (15%). ConClusions: Care 
for diabetes complications and additional treatments for diabetic people account 
for the highest part of the costs of diabetes care. The prevention of acute illness 
separate models to calculate cost of illness for each selected diseases. Medical 
resources included hospital stays, outpatient visits, ambulance service and reha-
bilitation. Results: Obesity-related and overweight-related expenses incurred by 
the state for treatment and management of patients were amounted to 10.2 billion 
rubles ($ 190.5 million) for stroke, 7.6 billion rubles ($ 141.9 million) for heart attack 
and 346.3 billion rubles ($ 6.5 billion) for diabetes mellitus. ConClusions: Obesity 
and overweight associated with significant economic burden on Russia’s health care 
system. There is a striking direct relationship between the cost of care on stroke, 
heart attack, diabetes mellitus and obesity and overweight that leading to increasing 
significant economic and social losses.
PCV77
medICAl Costs And resourCes ConsumPtIon In PAtIents wItH AtrIAl 
fIBrIllAtIon: An ItAlIAn oBserVAtIonAl study
Conti S1, Fornari C1, Botto G2, Inama G3, Tondo C4, Ciampichini R1, Chiodini V1, Mantovani 
LG1, Madotto F1, Cesana G1
1University of Milano - Bicocca, Monza, Italy, 2Ospedale S.Anna, Como, Italy, 3Istituto Clinico F. S. 
Camillo, Cremona, Italy, 4Centro Cardiologico Monzino, Milano, Italy
objeCtives: The prevalence of atrial fibrillation (AF), a common form of car-
diac arrhythmia, is rapidly rising in the developed world. Though several studies 
addressed the cost of illness, recent improvements in the disease management 
may have affected per capita medical resources consumption and costs, there-
fore it is desirable to provide updated estimates. This naturalistic study aimed at 
estimating costs and resource consumption related to AF from the perspective of 
the Italian Healthcare System in a large cohort of hospitalized cases. Methods: 
Using healthcare administrative databases (HADB) of Lombardy, a region in 
Northern Italy (10 million dwellers), we identified the cohort of residents who 
underwent a first hospitalization with a diagnosis of AF between 2003 and 2009, 
after a wash-out period of 3 years. We followed them until 2010, death or emi-
gration, extracting from HADB information on hospitalizations, drug prescrip-
tions and outpatient visits with related direct costs. We estimated mean annual 
resources consumption per 100 subjects and mean annual per capita cost through 
the Bang and Tsiatis approach. Results: We recruited a cohort of 143,022 sub-
jects (49% males), with a mean age of 75 years (±12 standard deviation) and a 
mean survival time of 5 years (95% confidence interval (CI): 5.0; 5.1) from baseline. 
Mean annual per-capita expenditure was 4,008€ (95%CI: 3,981; 4,039), of which 
65.2% was absorbed by hospitalizations, 18.5% by drug prescriptions and 16.3% 
by outpatient visits. We estimated 84.7 hospital admissions, the main driver of 
costs, per 100 subjects per year (95%CI: 83.8; 85.6), of which 17.0 (95%CI: 16.8; 
17.2) with an AF diagnosis. ConClusions: In line with literature, our results 
highlighted a high burden of AF, with large per capita healthcare expenditures 
and a high number of hospitalizations. Since AF has been described as an epi-
demic, increased attention should be devoted to the management of such 
disease.
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objeCtives: To estimate direct medical costs of cardiovascular (CV) events in the 
UK: myocardial infarction (MI), ischemic stroke (IS), heart failure (HF), transient 
ischemic attack (TIA), unstable angina (UA), and revascularisation. Methods: We 
used 2006-2012 Clinical Practice Research Datalink and Hospital Episode Statistics 
data to identify individuals with their first and, if present, repeated CV-related 
hospitalisations. Patients > 18 years receiving lipid-modifying therapy within 180 
days before the CV event were followed for 36 months, death, or loss to follow 
up. Patients were classified as CV Low/Moderate Risk, CV High Risk and CV Event 
History. Baseline (12 months before first CV event), acute (first 6 months after-
ward) and long-term costs (subsequent 30 months, annualised) were estimated 
by applying 2014 UK costs to drugs, hospitalisations and visits. Incremental CV 
event-related costs were calculated as the difference from baseline, reporting means 
across all cohorts and ranking cohort-specific means. Results: There were 6,408 
patients in CV Low/Moderate Risk, 17,685 in the CV High Risk, and 5,274 in CV Event 
History cohorts. Across the three cohorts, mean incremental acute CV event costs 
for revascularisation were £5,669 (£5,468-£5,823), MI £4,277 (£3,707-4,573), IS £3638 
(£3,472-4,572), HF £2,635 (£ 2390-£3461), UA £2,229 (£2063-£2489) and TIA £1,572 
(£1441-£1814). Mean incremental long-term costs were as follows: HF £1,129 (-£37-
£2829), MI £959 (£515-£1385), IS £953 (£682-£1072), TIA £793 (£340-£1692), UA £373 
(£319-£677), and revascularisation -£221 (-£411-£599). Costs of CV Low/Moderate Risk 
cohort ranked the lowest; costs of CV Event History were the highest. Hospitalisation 
costs were the primary drivers for both periods. ConClusions: Revascularisation 
and MI are the costliest CV events. The costs are the highest in the acute phase dur-
ing the first 6 months after a CV event and generally remain higher compared with 
pre-event period. Using real-world evidence, the economic burden of CV patients 
in the UK is substantial.
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objeCtives: The recently-observed trend towards the stroke patients in raises 
the economic concerns. Cost-of-illness (COI) analysis is the main method of 
providing an overall view on the economic impact of a disease. the main objec-
tive of this study is to estimate the economic burden of stroke. Methods: The 
